DIFFERENTIATION OF MAST CELL PROGENITORS

肥大细胞祖细胞的分化

基本信息

  • 批准号:
    3070990
  • 负责人:
  • 金额:
    $ 6.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1989
  • 资助国家:
    美国
  • 起止时间:
    1989-08-01 至 1994-07-31
  • 项目状态:
    已结题

项目摘要

Mast cell differentiation in vitro is accompanied by large-scale phenotypic changes as progenitors become IgE receptor-positive, granulated mast cells. Many of the phenotypic changes occur by expression of gene products unique to mast cells and basophils. Although these features make for an attractive model system for studies of cellular differentiation, the lack of a defined progenitor for mast cells (most investigators use unfractionated bone marrow) and the use of IL-3 to generate long term mast cell cultures has not allowed for a narrowly-focused window on the phenotypic changes. We have defined a late, committed stage in the differentiation of the mast cell progenitor just prior to granulation. This mast cell-committed progenitor does not require IL-3 of differentiation but does require factors provided by fibroblasts from connective tissue such as embryonic skin. This model system provides unique advantages to analyze mastocytogenesis, a process important in the development of diseases of immediate hypersensitivity. First, the in vitro differentiation system will be used to follow discrete changes in late-stage progenitor cells responding to defined factors. Preparations of isolated mast cell-committed progenitors will be phenotyped and triggered with purified fibroblast-derived factor. Cell activation will be monitored by following the mobilization of intracellular calcium and incorporation of tritiated thymidine. Changes in expression of high affinity IgE receptors, growth factor receptors, histamine biosynthesis, and granule assembly will correlate in sequence with signal transduction. Second, the differentiation system will be adapted for rat studies in order to detect chymase, RMCP-II, carboxypeptidase A, or heparin proteoglycan in mast cells derived from culture on embryonic skin monolayers. This will allow us to study mast cell heterogeneity (mucosal vs connective tissue type) in an in vitro system. Third, the factors which cause the transition of the primitive bone marrow progenitor for mast cells to progress to the IL-3 independent committed progenitor will be determined by experiments designed to mimic in vitro the two most likely in vivo milieus that give rise to the committed progenitor: completely degranulated mast cells from the gut mucosa draining into the MLN, or bone marrow progenitors trafficking to the MLN as a primitive progenitor and progressing into committed progenitors in situ.
肥大细胞的体外分化伴随着大规模的分化

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THOMAS F HUFF其他文献

THOMAS F HUFF的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THOMAS F HUFF', 18)}}的其他基金

DIFFERENTIATION OF MAST CELL PROGENITORS
肥大细胞祖细胞的分化
  • 批准号:
    3070989
  • 财政年份:
    1989
  • 资助金额:
    $ 6.8万
  • 项目类别:
DIFFERENTIATION OF MAST CELL PROGENITORS
肥大细胞祖细胞的分化
  • 批准号:
    3070993
  • 财政年份:
    1989
  • 资助金额:
    $ 6.8万
  • 项目类别:
DIFFERENTIATION OF MAST CELL PROGENITORS
肥大细胞祖细胞的分化
  • 批准号:
    3070992
  • 财政年份:
    1989
  • 资助金额:
    $ 6.8万
  • 项目类别:
DIFFERENTIATION OF MAST CELL PROGENITORS
肥大细胞祖细胞的分化
  • 批准号:
    3070991
  • 财政年份:
    1989
  • 资助金额:
    $ 6.8万
  • 项目类别:
MAST CELL DIFFERENTIATION IN VITRO
肥大细胞体外分化
  • 批准号:
    2062987
  • 财政年份:
    1988
  • 资助金额:
    $ 6.8万
  • 项目类别:
STUDIES OF MAST CELL DIFFERENTIATION IN VITRO
肥大细胞体外分化的研究
  • 批准号:
    3138961
  • 财政年份:
    1988
  • 资助金额:
    $ 6.8万
  • 项目类别:
MAST CELL DIFFERENTIATION IN VITRO
肥大细胞体外分化
  • 批准号:
    3138958
  • 财政年份:
    1988
  • 资助金额:
    $ 6.8万
  • 项目类别:
MAST CELL DIFFERENTIATION IN VITRO
肥大细胞体外分化
  • 批准号:
    2607767
  • 财政年份:
    1988
  • 资助金额:
    $ 6.8万
  • 项目类别:
MAST CELL DIFFERENTIATION IN VITRO
肥大细胞体外分化
  • 批准号:
    3138963
  • 财政年份:
    1988
  • 资助金额:
    $ 6.8万
  • 项目类别:
MAST CELL DIFFERENTIATION IN VITRO
肥大细胞体外分化
  • 批准号:
    2003441
  • 财政年份:
    1988
  • 资助金额:
    $ 6.8万
  • 项目类别:

相似海外基金

Study on the mechanism of prolonged half-life of blood IgY by unique antibody receptor and its application to immune enhancement in birds
独特抗体受体延长血液IgY半衰期的机制研究及其在禽类免疫增强中的应用
  • 批准号:
    23H02361
  • 财政年份:
    2023
  • 资助金额:
    $ 6.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
  • 批准号:
    nhmrc : GNT1124162
  • 财政年份:
    2017
  • 资助金额:
    $ 6.8万
  • 项目类别:
    Early Career Fellowships
Innate immune functions of the intracellular antibody receptor TRIM21
细胞内抗体受体 TRIM21 的先天免疫功能
  • 批准号:
    nhmrc : 1124162
  • 财政年份:
    2017
  • 资助金额:
    $ 6.8万
  • 项目类别:
    Early Career Fellowships
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
  • 批准号:
    9300976
  • 财政年份:
    2015
  • 资助金额:
    $ 6.8万
  • 项目类别:
Mechanism and engineering of IgG-based monoclonal antibody/receptor interactions
基于 IgG 的单克隆抗体/受体相互作用的机制和工程
  • 批准号:
    9920805
  • 财政年份:
    2015
  • 资助金额:
    $ 6.8万
  • 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
  • 批准号:
    8900121
  • 财政年份:
    2012
  • 资助金额:
    $ 6.8万
  • 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
  • 批准号:
    8225814
  • 财政年份:
    2012
  • 资助金额:
    $ 6.8万
  • 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
  • 批准号:
    8699511
  • 财政年份:
    2012
  • 资助金额:
    $ 6.8万
  • 项目类别:
Augmenting Chimeric Antibody Receptor Directed T cell Therapy for Cancer
增强嵌合抗体受体定向 T 细胞治疗癌症
  • 批准号:
    8525355
  • 财政年份:
    2012
  • 资助金额:
    $ 6.8万
  • 项目类别:
Small Grants for Exploratory Research: Separation of Cells and Biological Macromolecules by Antibody Receptor Coated Magnetic Vesicles and Ferritin Conjugates
探索性研究小额资助:通过抗体受体包被的磁囊和铁蛋白缀合物分离细胞和生物大分子
  • 批准号:
    9115537
  • 财政年份:
    1991
  • 资助金额:
    $ 6.8万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了